

## **CLINICAL INVESTIGATION OF THE EFFECTS OF TOPICAL SERUM AND SHAMPOO CONTAINING SYNTHETIC THYMUS PEPTIDES (STPL2) ON ANDROGENETIC ALOPECIA AND CHRONIC TELOGEN EFFLUVIUM IN MEN AND WOMEN**

Dr. Mauro Barbareschi MD

Dipartimento Anestesiologia, Terapia Intensiva e Scienze Dermatologiche Università di Milano

IRCCS Fondazione Ca' Granda – Ospedale Maggiore – Policlinico Milano

Arena Nicola (ME), Bazzigaluppi Franco (LO), Bevacqua Gilda (Roma), Bianchi Arianna (TO), Ciasulli Annalisa (Roma), Claudi Roberto (S. Severino Marche - AN), Convertini Luca (BR), Domaneschi Elisabetta (CR), Esposito Giovanni (Marano - NA), Falvo Gabriele (Roma), Ferrauto Ettore (PI), Foglia Rosetta (PR), Forleo Pietro (BR), Ghiselli Elena (NO), Gigantino Mauro (NO), Gubbini Anna Maria (Fano), Guida Marco (TO), Lanfranchi Maria Luisa (NO), Mancini Giulio (Roma), Mazzei Wilma (TO), Negri Vittoria (TO), Orecchia Giovanni (PV), Pecorari Gemma (RE), Pelle' Stefano (LE), Petronella Nita (AN), Pia Palmieri Isabella (ME), Pretto Emanuela (PR), Robotti Stefania (NO), Salvati Alessandro (Viareggio - LU), Sategna Franco (Roma), Simoncini Claudia (Fabriano - AN), Trinca Armati Francesco (Roma).

In Press  
Submitted to  
Journal of Dermatology

## SUMMARY

### INTRODUCTION

The aim of the paper has been to study during a period of six month the efficacy and the tolerability of both the serum and shampoo containing synthetic low molecular weight thymus peptides (STPL2), in the initial phases of Androgenetic Alopecia (AGA) and chronic Telogen Effluvium (TE).

### SUBJECTS

337 study subjects (men and women) have been enrolled and divided in following groups:

- 1) 70 men (mean age 30,72 yrs) with AGA,
- 2) 59 men (mean age 35,86 yrs) with chronic TE
- 3) 53 Women (mean age 42,07 yrs) with AGA
- 4) 184 Women (mean age 36,94 yrs) with chronic TE

### METHODS

The treatment schedule was as follows:

- Serum: once a day application for a total period of treatment of 24 weeks;
- Shampoo: three times /week during the study period of 24 weeks.

All the subjects underwent a


1. Pull test
2. Evaluation of symptoms (e.g. seborrhea, erythema and pruritus).

Tolerability and cosmetic acceptance were evaluated after 180 days of treatment.

### RESULTS

#### Men

In male subjects with AGA the improvement measured by the pull test has been of 94% with a mean symptoms improvement of 89%.



**Figure 1.** Pull test after 180 days of treatment;  
Excellent: Improvement of 3 levels of Pull test  
Good: Improvement of 2 levels of Pull test  
Fair : Improvement of 1 levels of Pull test  
Poor: No change or deterioration of Pull test

In male TE subjects the improvement of pull test has been of 98% with a mean symptoms' improvement of 77%.



**Figure 2.** Pull test after 180 days of treatment;  
Excellent: Improvement of 3 levels of Pull test  
Good: Improvement of 2 levels of Pull test  
Fair : Improvement of 1 levels of Pull test  
Poor: No change or deterioration of Pull test

## Women


In female AGA subjects the improvement of the pull test has been of 98% with a mean symptom's improvement of 95%



**Figure 3.** Pull test after 180 days of treatment;  
Excellent: Improvement of 3 levels of Pull test  
Good: Improvement of 2 levels of Pull test  
Fair : Improvement of 1 levels of Pull test  
Poor: No change or deterioration of Pull test

In female TE subjects the improvement of pull test has been of 99% with a mean symptoms' improvement of 95%.


In all groups the tolerability was referred to as positive in 100% of cases and no



side effects were recorded.

**Figure 4.** Pull test after 180 days of treatment;  
Excellent: Improvement of 3 levels of Pull test  
Good: Improvement of 2 levels of Pull test  
Fair : Improvement of 1 levels of Pull test  
Poor: No change or deterioration of Pull test

The cosmetic acceptance/tolerance was also referred as positive in 98% of the cases.



**Figure 5.** Opinion of tester at the end of treatment.

## CONCLUSION

In conclusion, synthetic thymus peptides showed significant efficacy and tolerability in the clinical treatment of initial AGA and chronic TE in men and women after a six month-treatment.